Published in N Engl J Med on April 13, 2000
How to calculate the dose of chemotherapy. Br J Cancer (2002) 1.75
Evolving risk of therapy-related acute myeloid leukemia following cancer chemotherapy among adults in the United States, 1975-2008. Blood (2013) 1.64
Clinical practice guidelines for the care and treatment of breast cancer: 15. Treatment for women with stage III or locally advanced breast cancer. CMAJ (2004) 1.51
Presumed benefit: lessons from the American experience with marrow transplantation for breast cancer. BMJ (2002) 1.50
Long-term outcome of patients with metastatic breast cancer treated with high-dose chemotherapy and transplantation of purified autologous hematopoietic stem cells. Biol Blood Marrow Transplant (2011) 1.49
Methylguanine methyltransferase-mediated in vivo selection and chemoprotection of allogeneic stem cells in a large-animal model. J Clin Invest (2003) 1.27
High-dose chemotherapy plus autologous bone marrow transplantation for metastatic breast cancer. N Engl J Med (2000) 1.17
Improvement of survival and prospect of cure in patients with metastatic breast cancer. Breast Cancer (2011) 1.15
Interdisciplinary GoR level III Guidelines for the Diagnosis, Therapy and Follow-up Care of Breast Cancer: Short version - AWMF Registry No.: 032-045OL AWMF-Register-Nummer: 032-045OL - Kurzversion 3.0, Juli 2012. Geburtshilfe Frauenheilkd (2013) 1.14
The ethical use of mandatory research biopsies. Nat Rev Clin Oncol (2011) 1.11
Regenerative therapy after cancer: what are the risks? Tissue Eng Part B Rev (2010) 1.01
Chemotherapy-induced neutropenia as a prognostic factor in advanced non-small-cell lung cancer: results from Japan Multinational Trial Organization LC00-03. Br J Cancer (2009) 0.99
Continuous low-dose cyclophosphamide and methotrexate combined with celecoxib for patients with advanced cancer. Br J Cancer (2011) 0.99
Mesenchymal stem cell secretome and regenerative therapy after cancer. Biochimie (2013) 0.93
Cardiac toxicity of trastuzumab in metastatic breast cancer patients previously treated with high-dose chemotherapy: a retrospective study. Br J Cancer (2006) 0.91
Chemotherapy and signaling: How can targeted therapies supercharge cytotoxic agents? Cancer Biol Ther (2010) 0.89
Whither high-dose chemotherapy in breast cancer? Breast Cancer Res (2000) 0.86
The pharmacologic basis of high dose chemotherapy with haematopoietic stem cell support for solid tumours. Br J Cancer (2001) 0.83
The inverted pyramid of biomarker-driven trials. Nat Rev Clin Oncol (2011) 0.82
Unproven stem cell-based interventions and achieving a compromise policy among the multiple stakeholders. BMC Med Ethics (2015) 0.82
Management of advanced adult soft tissue sarcoma. Sarcoma (2003) 0.79
High-dose sequential epirubicin and cyclophosphamide with peripheral blood stem cell support for advanced breast cancer: results of a phase II study. Br J Cancer (2001) 0.78
High-Dose Chemotherapy Followed by Peripheral and/or Bone Marrow Stem Cell Transplant in Patients With Advanced Sarcoma: Experience of a Canadian Centre. Sarcoma (2004) 0.78
Toxicity of the high-dose chemotherapy CTC regimen (cyclophosphamide, thiotepa, carboplatin): the Netherlands Cancer Institute experience. Br J Cancer (2003) 0.78
Toward a universal treatment for cancer: cell inflation assisted chemotherapy. Cancer Med (2013) 0.77
Double high-dose chemotherapy with adriamycin, paclitaxel, cyclophosphamide, and thiotepa followed by autologous peripheral blood stem cell transplantation in women with metastatic breast cancer. J Cancer Res Clin Oncol (2003) 0.77
Stem-cell transplantation for the treatment of advanced solid tumors. Springer Semin Immunopathol (2004) 0.77
A phase I/II study of 4 monthly courses of high-dose cyclophosphamide and thiotepa for metastatic breast cancer patients. Br J Cancer (2002) 0.75
Randomized trials of high-dose chemotherapy in breast cancer: fraud, the press and the data (or lessons learned in medical policy governing clinical research). Trans Am Clin Climatol Assoc (2002) 0.75
Long-term survival after high-dose chemotherapy followed by peripheral stem cell rescue for high-risk, locally advanced/inflammatory, and metastatic breast cancer. Biol Blood Marrow Transplant (2012) 0.75
Highly favorable outcome in BRCA-mutated metastatic breast cancer patients receiving high-dose chemotherapy and autologous hematopoietic stem cell transplantation. Bone Marrow Transplant (2016) 0.75
The diffusion of docetaxel in patients with metastatic prostate cancer. J Natl Cancer Inst (2014) 0.75
High-dose chemotherapy plus hematopoietic stem-cell rescue for metastatic breast cancer. N Engl J Med (2000) 0.75
High-dose chemotherapy plus hematopoietic stem-cell rescue for metastatic breast cancer. N Engl J Med (2000) 0.75
Dose intensity and autologous stem cell transplantation as salvage therapy for pediatric primary CNS malignancies. Int J Nanomedicine (2014) 0.75
From evidence to clinical practice in blood and marrow transplantation. Blood Rev (2015) 0.75
Inefficiencies and Patient Burdens in the Development of the Targeted Cancer Drug Sorafenib: A Systematic Review. PLoS Biol (2017) 0.75
High-dose chemotherapy of cyclophosphamide, thiotepa, and carboplatin (CTCb) followed by autologous stem-cell transplantation for metastatic breast cancer patients: a 6-year follow-up result. Cancer Res Treat (2005) 0.75
High-dose chemotherapy plus hematopoietic stem-cell rescue for metastatic breast cancer. N Engl J Med (2000) 0.75
Long-Term Outcome of Inflammatory Breast Cancer Compared to Non-Inflammatory Breast Cancer in the Setting of High-Dose Chemotherapy with Autologous Hematopoietic Cell Transplantation. J Cancer (2017) 0.75
The yield and safety of thoracentesis in hematopoietic stem cell transplantation recipients. Lung (2007) 0.75
A Predictive Mathematical Modeling Approach for the Study of Doxorubicin Treatment in Triple Negative Breast Cancer. Sci Rep (2017) 0.75
Levamisole and fluorouracil for adjuvant therapy of resected colon carcinoma. N Engl J Med (1990) 11.57
Thresholds for therapies: highlights of the St Gallen International Expert Consensus on the primary therapy of early breast cancer 2009. Ann Oncol (2009) 9.18
Comparison of a standard regimen (CHOP) with three intensive chemotherapy regimens for advanced non-Hodgkin's lymphoma. N Engl J Med (1993) 6.77
The influence of margin width on local control of ductal carcinoma in situ of the breast. N Engl J Med (1999) 6.16
Chemotherapy compared with autologous or allogeneic bone marrow transplantation in the management of acute myeloid leukemia in first remission. N Engl J Med (1998) 5.98
Meeting highlights: international expert consensus on the primary therapy of early breast cancer 2005. Ann Oncol (2005) 5.41
Meeting highlights: International Consensus Panel on the Treatment of Primary Breast Cancer. Seventh International Conference on Adjuvant Therapy of Primary Breast Cancer. J Clin Oncol (2001) 5.31
Hematopoietic engraftment and survival in adult recipients of umbilical-cord blood from unrelated donors. N Engl J Med (2001) 5.14
PADGEM protein: a receptor that mediates the interaction of activated platelets with neutrophils and monocytes. Cell (1989) 3.95
Rapid hematopoietic recovery after coinfusion of autologous-blood stem cells and culture-expanded marrow mesenchymal stem cells in advanced breast cancer patients receiving high-dose chemotherapy. J Clin Oncol (2000) 3.94
Fluorouracil plus levamisole as effective adjuvant therapy after resection of stage III colon carcinoma: a final report. Ann Intern Med (1995) 3.83
Meeting highlights: International Consensus Panel on the Treatment of Primary Breast Cancer. J Natl Cancer Inst (1998) 3.50
Allogeneic mesenchymal stem cell infusion for treatment of metachromatic leukodystrophy (MLD) and Hurler syndrome (MPS-IH). Bone Marrow Transplant (2002) 3.24
Centrosome hypertrophy in human breast tumors: implications for genomic stability and cell polarity. Proc Natl Acad Sci U S A (1998) 3.23
Diagnosis and treatment of transplantation-associated thrombotic microangiopathy: real progress or are we still waiting? Bone Marrow Transplant (2007) 3.18
Primary breast sarcoma: clinicopathologic series from the Mayo Clinic and review of the literature. Br J Cancer (2004) 3.10
Prognostic impact of amenorrhoea after adjuvant chemotherapy in premenopausal breast cancer patients with axillary node involvement: results of the International Breast Cancer Study Group (IBCSG) Trial VI. Eur J Cancer (1998) 3.03
Postchemotherapy rheumatism. J Clin Oncol (1993) 3.01
Fluconazole prophylaxis of fungal infections in patients with acute leukemia. Results of a randomized placebo-controlled, double-blind, multicenter trial. Ann Intern Med (1993) 2.90
17q23 amplifications in breast cancer involve the PAT1, RAD51C, PS6K, and SIGma1B genes. Cancer Res (2000) 2.81
A national survey of asthma prevalence, severity, and treatment in Great Britain. Arch Dis Child (1994) 2.74
Effects of trimethoprim on folate metabolism in man. Clin Pharmacol Ther (1968) 2.68
Increased HER2 with U.S. Food and Drug Administration-approved antibody. J Clin Oncol (1999) 2.48
Durable treatment-free remission after high-dose cyclophosphamide therapy for previously untreated severe aplastic anemia. Ann Intern Med (2001) 2.47
American Society of Clinical Oncology guideline on the role of bisphosphonates in breast cancer. American Society of Clinical Oncology Bisphosphonates Expert Panel. J Clin Oncol (2000) 2.39
Integrin alpha IIb beta 3 mediates binding of the Lyme disease agent Borrelia burgdorferi to human platelets. Proc Natl Acad Sci U S A (1993) 2.36
The influence of young age on outcome in early stage breast cancer. Int J Radiat Oncol Biol Phys (1994) 2.17
Metaplastic breast cancer: prognosis and response to systemic therapy. Ann Oncol (1999) 2.12
Intergroup study of fluorouracil plus levamisole as adjuvant therapy for stage II/Dukes' B2 colon cancer. J Clin Oncol (1995) 2.02
The impact of a multidisciplinary breast cancer center on recommendations for patient management: the University of Pennsylvania experience. Cancer (2001) 1.99
Bisphosphonates directly regulate cell proliferation, differentiation, and gene expression in human osteoblasts. Cancer Res (2000) 1.98
Identifying breast cancer patients at high risk for bone metastases. J Clin Oncol (2000) 1.91
Pervasive occult gastrointestinal bleeding in an Alaska native population with prevalent iron deficiency. Role of Helicobacter pylori gastritis. JAMA (1997) 1.89
Similar outcomes using myeloablative vs reduced-intensity allogeneic transplant preparative regimens for AML or MDS. Bone Marrow Transplant (2011) 1.82
Chronic graft-versus-host disease: clinical manifestation and therapy. Bone Marrow Transplant (2001) 1.82
Recommended guidelines for the management of autologous and allogeneic bone marrow transplantation. A report from the Eastern Cooperative Oncology Group (ECOG) Ann Intern Med (1994) 1.81
Purification and properties of a nuclear exoribonuclease from Ehrlich ascites tumor cells. Proc Natl Acad Sci U S A (1967) 1.77
High-dose chemotherapy with autologous hematopoietic stem-cell support for breast cancer in North America. J Clin Oncol (1997) 1.75
Weight change in women treated with adjuvant therapy or observed following mastectomy for node-positive breast cancer. J Clin Oncol (1990) 1.74
Randomized clinical trial of diethylstilbestrol versus tamoxifen in postmenopausal women with advanced breast cancer. N Engl J Med (1981) 1.70
Determinants of postembolization syndrome after hepatic chemoembolization. J Vasc Interv Radiol (2001) 1.70
Specific mutations in a viral RNA pseudoknot drastically change ribosomal frameshifting efficiency. Proc Natl Acad Sci U S A (1999) 1.68
Prolonged survival associated with early lymphocyte recovery after autologous hematopoietic stem cell transplantation for patients with metastatic breast cancer. Bone Marrow Transplant (2001) 1.67
Adherence to a dietary fat intake reduction program in postmenopausal women receiving therapy for early breast cancer. The Women's Intervention Nutrition Study. J Clin Oncol (1993) 1.64
A novel hearing-loss-related mutation occurring in the GJB2 basal promoter. J Med Genet (2007) 1.62
Comorbidity indices in hematopoietic stem cell transplantation: a new report card. Bone Marrow Transplant (2005) 1.61
Cox-2 inhibition enhances the activity of sunitinib in human renal cell carcinoma xenografts. Br J Cancer (2013) 1.57
MDR1 gene expression in lung cancer. J Natl Cancer Inst (1989) 1.57
Bone marrow-derived mesenchymal stem cells remain host-derived despite successful hematopoietic engraftment after allogeneic transplantation in patients with lysosomal and peroxisomal storage diseases. Exp Hematol (1999) 1.55
Familial patterns of thoracic aortic aneurysms. Arch Surg (1999) 1.53
Immunoablative high-dose cyclophosphamide without stem-cell rescue for refractory, severe autoimmune disease. Ann Intern Med (1998) 1.51
Randomized cross-over trial of progenitor-cell mobilization: high-dose cyclophosphamide plus granulocyte colony-stimulating factor (G-CSF) versus granulocyte-macrophage colony-stimulating factor plus G-CSF. J Clin Oncol (2000) 1.50
Organic solvent exposure and hearing loss in a cohort of aluminium workers. Occup Environ Med (2007) 1.49
Maximum-tolerated doses of ifosfamide, carboplatin, and etoposide given over 6 days followed by autologous stem-cell rescue: toxicity profile. J Clin Oncol (1995) 1.49
Factors correlated with progression-free survival after high-dose chemotherapy and hematopoietic stem cell transplantation for metastatic breast cancer. JAMA (1999) 1.49
Myeloablative therapy with autologous stem cell rescue for patients with Ewing sarcoma. Bone Marrow Transplant (2008) 1.46
Hypoxia inhibits human bladder smooth muscle cell proliferation: a potential mechanism of bladder dysfunction. Neurourol Urodyn (2004) 1.46
In vivo gene therapy of metachromatic leukodystrophy by lentiviral vectors: correction of neuropathology and protection against learning impairments in affected mice. Nat Med (2001) 1.46
High-dose cytosine arabinoside therapy for refractory leukemia. Blood (1983) 1.44
Influence of patient characteristics, socioeconomic factors, geography, and systemic risk on the use of breast-sparing treatment in women enrolled in adjuvant breast cancer studies: an analysis of two intergroup trials. J Clin Oncol (1996) 1.43
High-dose chemotherapy and autologous stem-cell transplantation for ovarian cancer: an autologous blood and marrow transplant registry report. Ann Intern Med (2000) 1.42
Multicenter randomized clinical trial of goserelin versus surgical ovariectomy in premenopausal patients with receptor-positive metastatic breast cancer: an intergroup study. J Clin Oncol (1998) 1.42
High-dose cytarabine and daunorubicin as consolidation therapy for acute myeloid leukemia in first remission: long-term follow-up and results. J Clin Oncol (1989) 1.41
'A rose by any other name would smell as sweet', or would it? Bone Marrow Transplant (2013) 1.41
Corynebacterium striatum: a diphtheroid with pathogenic potential. Clin Infect Dis (1993) 1.41
Right ventricle-sparing heart transplant: promising new technique for recipients with pulmonary hypertension. Ann Thorac Surg (2000) 1.40
Autologous stem-cell transplant after conventional dose adjuvant chemotherapy for high-risk breast cancer: impact on the delivery of local-regional radiation therapy. Ann Oncol (1999) 1.40
Acute myocardial infarction in pediatric systemic lupus erythematosus. J Pediatr (1990) 1.39
Bone marrow and blood findings after marrow transplantation and rhGM-CSF therapy. Am J Clin Pathol (1992) 1.38
Breast conservation therapy for invasive breast cancer: a review of prior trials and the Mayo Clinic experience. Mayo Clin Proc (1994) 1.38
Expression of cathepsin L in human tumors. Cancer Res (1991) 1.37
Comparison of preparative regimens in transplants for children with acute lymphoblastic leukemia. J Clin Oncol (2000) 1.36
Ocular complications of systemic cancer chemotherapy. Surv Ophthalmol (1990) 1.36
Clinical consequences of alterations in platelet transfusion dose: a prospective, randomized, double-blind trial. Transfusion (1999) 1.34
Autologous transplantation for diffuse aggressive non-Hodgkin's lymphoma in patients never achieving remission: a report from the Autologous Blood and Marrow Transplant Registry. J Clin Oncol (2001) 1.34
Prophylactic tranexamic acid decreases bleeding after cardiac operations. J Thorac Cardiovasc Surg (1990) 1.33
Antimicrobial properties and mode of action of the pyrrothine holomycin. Antimicrob Agents Chemother (2001) 1.31
NCCN Practice Guidelines for Cancer Pain. Oncology (Williston Park) (2000) 1.30
Placental transfusion and hyperbilirubinemia in the premature. Pediatrics (1972) 1.30
Donor lymphocyte infusions: the long and winding road: how should it be traveled? Bone Marrow Transplant (2008) 1.30
Iron overload in hematopoietic cell transplantation. Bone Marrow Transplant (2008) 1.29
Purification of T antigen from nuclei of simian virus 40-induced hamster tumors. J Virol (1967) 1.29
Work site group meetings and the effectiveness of a televised smoking cessation intervention. Am J Community Psychol (1987) 1.29
Allogeneic bone marrow transplantation for low-grade lymphoma. Blood (1998) 1.29
First observation of the Greisen-Zatsepin-Kuzmin suppression. Phys Rev Lett (2008) 1.29
Functional characterization of the novel neuronal nicotinic acetylcholine receptor ligand GTS-21 in vitro and in vivo. Pharmacol Biochem Behav (1997) 1.28
Natural history, pathogenesis, and etiology of thoracic aortic aneurysms and dissections. Cardiol Clin (1999) 1.28
Randomized trial of diethylstilbestrol vs. tamoxifen in postmenopausal women with metastatic breast cancer. An updated analysis. Breast Cancer Res Treat (1999) 1.27
Molecular markers in male breast carcinoma. Cancer (1998) 1.26
Mesenchymal stem cells: heading into the clinic. Bone Marrow Transplant (2001) 1.26
Prediction of node-negative breast cancer outcome by histologic grading and S-phase analysis by flow cytometry: an Eastern Cooperative Oncology Group Study (2192). Am J Clin Oncol (2001) 1.26
Intent-to-treat analysis of the placebo-controlled trial of letrozole for extended adjuvant therapy in early breast cancer: NCIC CTG MA.17. Ann Oncol (2008) 1.24
Microsecond atomic force sensing of protein conformational dynamics: implications for the primary light-induced events in bacteriorhodopsin. Proc Natl Acad Sci U S A (1997) 1.23
Clostridium difficile-associated disease in human stem cell transplant recipients: coming epidemic or false alarm? Bone Marrow Transplant (2008) 1.23
bcl-2, p53, and response to tamoxifen in estrogen receptor-positive metastatic breast cancer: a Southwest Oncology Group study. J Clin Oncol (1997) 1.23
An -N-acetyl-D-glycosamine binding lectin from Bandeiraea simplicifolia seeds. Arch Biochem Biophys (1976) 1.22